Study of STA-9090, Administered Twice-Weekly in Patients With Solid Tumors

• Status: Unknown status
• Trial end date: 2014-11-01
• Target enrollment: 0
• Participant gender: All

Summary

An open-label dose escalation study of patients with solid tumors treated with STA-9090 (ganetespib)

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Synta Pharmaceuticals Corp.

Criteria

Inclusion Criteria:

• Patients must be documented to be refractory or not candidates for current approved therapies. - Must have anECOG status 0-2. - Peripheral neuropathy ?2.

• Must have acceptable organ and marrow function per protocol parameters.

• No clinically significant ventricular arrythmias or ischemia.

Exclusion Criteria:

• Must not be pregnant or breastfeeding. -No chemotherapy or radiation within 3 weeks..

• No previous radiation to >25% of total bone marrow.

• No previous high dose chemotherapy with autologous or allogeniec hematopoietic stem cell transplantation.

• No primary brain tumors or active brain metastases.

• No use of any investigational agents within 4 weeks.

• No treatment with chronic immunosuppressants.

• No uncontrolled, intercurrent illness.